Skip to Content
Merck
CN
  • Amyloid-β and Alzheimer's disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions.

Amyloid-β and Alzheimer's disease type pathology differentially affects the calcium signalling toolkit in astrocytes from different brain regions.

Cell death & disease (2013-05-11)
A A Grolla, J A Sim, D Lim, J J Rodriguez, A A Genazzani, A Verkhratsky
ABSTRACT

The entorhinal-hippocampal circuit is severely affected in Alzheimer's disease (AD). Here, we demonstrate that amyloid-β (Aβ) differentially affects primary cultured astrocytes derived from the entorhinal cortex (EC) and from the hippocampus from non-transgenic controls and 3xTg-AD transgenic mice. Exposure to 100 nM of Aβ resulted in increased expression of the metabotropic glutamate receptor type 5 (mGluR5) and its downstream InsP3 receptor type 1 (InsP3R1) in hippocampal but not in EC astrocytes. Amplitudes of Ca(2+) responses to an mGluR5 agonist, DHPG, and to ATP, another metabotropic agonist coupled to InsP3Rs, were significantly increased in Aβ-treated hippocampal but not in EC astrocytes. Previously we demonstrated that senile plaque formation in 3xTg-AD mice triggers astrogliosis in hippocampal but not in EC astrocytes. The different sensitivities of the Ca(2+) signalling toolkit of EC versus hippocampal astrocytes to Aβ may account for the lack of astrogliosis in the EC, which in turn can explain the higher vulnerability of this region to AD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-GFAP antibody produced in goat, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-IP3 Receptor 1 Antibody, Chemicon®, from rabbit
Sigma-Aldrich
Anti-Metabotropic Glutamate Receptor 5 Antibody, pain, Chemicon®, from rabbit